Raras
Buscar doenças, sintomas, genes...
Tumor de células dendríticas
ORPHA:98289CID-10 · C96.4DOENÇA RARA

Um tumor de células dendríticas é um tipo de tumor que se desenvolve a partir das células dendríticas, que são parte do sistema imunológico (o sistema de defesa do corpo). Geralmente, essa condição começa no sistema linfático e pode se espalhar para órgãos próximos ou para partes distantes do corpo (um processo chamado metástase). Os sintomas e a gravidade da doença dependem do subtipo (o tipo específico) e de onde o tumor está localizado.

Mantido por Agente Raras·Colaborar como especialista →

Introdução

O que você precisa saber de cara

📋

Um tumor de células dendríticas é um tipo de tumor que se desenvolve a partir das células dendríticas, que são parte do sistema imunológico (o sistema de defesa do corpo). Geralmente, essa condição começa no sistema linfático e pode se espalhar para órgãos próximos ou para partes distantes do corpo (um processo chamado metástase). Os sintomas e a gravidade da doença dependem do subtipo (o tipo específico) e de onde o tumor está localizado.

Pesquisas ativas
20 ensaios
56 total registrados no ClinicalTrials.gov
Publicações científicas
243 artigos
Último publicado: 2026 Jan 15
🏥
SUS: Sem cobertura SUSScore: 0%
CID-10: C96.4
Você se identifica com essa condição?
O Raras está aqui pra te apoiar — com ou sem diagnóstico

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Entender a doença

Do básico ao detalhe, leia no seu ritmo

Preparando trilha educativa...

Sinais e sintomas

O que aparece no corpo e com que frequência cada sintoma acontece

Partes do corpo afetadas

🫁
Pulmão
6 sintomas
🫃
Digestivo
5 sintomas
🩸
Sangue
4 sintomas
🧠
Neurológico
4 sintomas
📏
Crescimento
4 sintomas
🧬
Pele e cabelo
3 sintomas

+ 12 sintomas em outras categorias

Características mais comuns

Distensão abdominal
Contagem total de neutrófilos diminuída
Trombocitopenia
Dermatite seborreica
Dispneia
Anormalidade do sistema esquelético
42sintomas
Sem dados (42)

Os sintomas variam de pessoa para pessoa. Abaixo estão as 42 características clínicas mais associadas, ordenadas por frequência.

Distensão abdominalAbdominal distention
Contagem total de neutrófilos diminuídaDecreased total neutrophil count
TrombocitopeniaThrombocytopenia
Dermatite seborreicaSeborrheic dermatitis
DispneiaDyspnea

Linha do tempo da pesquisa

Publicações por ano — veja quando o interesse científico cresceu
Anos de pesquisa1desde 2026
Total histórico243PubMed
Últimos 10 anos86publicações
Pico202412 papers
Linha do tempo
2026Hoje · 2026🧪 1990Primeiro ensaio clínico📈 2024Ano de pico
Publicações por ano (últimos 10 anos)

Encontrou um erro ou informação desatualizada? Sugira uma correção →

Genética e causas

O que está alterado no DNA e como passa nas famílias

Genes associados

3 genes identificados com associação a esta condição.

BRAFSerine/threonine-protein kinase B-rafCandidate gene tested inAltamente restrito
FUNÇÃO

Protein kinase involved in the transduction of mitogenic signals from the cell membrane to the nucleus (Probable). Phosphorylates MAP2K1, and thereby activates the MAP kinase signal transduction pathway (PubMed:21441910, PubMed:29433126). Phosphorylates PFKFB2 (PubMed:36402789). May play a role in the postsynaptic responses of hippocampal neurons (PubMed:1508179)

LOCALIZAÇÃO

NucleusCytoplasmCell membrane

VIAS BIOLÓGICAS (4)
Spry regulation of FGF signalingParadoxical activation of RAF signaling by kinase inactive BRAFARMS-mediated activationSignalling to p38 via RIT and RIN
OUTRAS DOENÇAS (18)
Noonan syndrome 7LEOPARD syndrome 3melanoma, cutaneous malignant, susceptibility to, 1lung cancer
HGNC:1097UniProt:P15056
MAP2K1Dual specificity mitogen-activated protein kinase kinase 1Candidate gene tested inAltamente restrito
FUNÇÃO

Dual specificity protein kinase which acts as an essential component of the MAP kinase signal transduction pathway. Binding of extracellular ligands such as growth factors, cytokines and hormones to their cell-surface receptors activates RAS and this initiates RAF1 activation. RAF1 then further activates the dual-specificity protein kinases MAP2K1/MEK1 and MAP2K2/MEK2. Both MAP2K1/MEK1 and MAP2K2/MEK2 function specifically in the MAPK/ERK cascade, and catalyze the concomitant phosphorylation of

LOCALIZAÇÃO

Cytoplasm, cytoskeleton, microtubule organizing center, centrosomeCytoplasm, cytoskeleton, microtubule organizing center, spindle pole bodyCytoplasmNucleusMembrane

VIAS BIOLÓGICAS (10)
MAP2K and MAPK activationFrs2-mediated activationSignaling downstream of RAS mutantsSignaling by high-kinase activity BRAF mutantsSignaling by moderate kinase activity BRAF mutants
MECANISMO DE DOENÇA

Cardiofaciocutaneous syndrome 3

A form of cardiofaciocutaneous syndrome, a multiple congenital anomaly disorder characterized by a distinctive facial appearance, heart defects and intellectual disability. Heart defects include pulmonic stenosis, atrial septal defects and hypertrophic cardiomyopathy. Some affected individuals present with ectodermal abnormalities such as sparse, friable hair, hyperkeratotic skin lesions and a generalized ichthyosis-like condition. Typical facial features are similar to Noonan syndrome. They include high forehead with bitemporal constriction, hypoplastic supraorbital ridges, downslanting palpebral fissures, a depressed nasal bridge, and posteriorly angulated ears with prominent helices. Distinctive features of CFC3 include macrostomia and horizontal shape of palpebral fissures.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
99.1 TPM
Cérebro - Hemisfério cerebelar
89.3 TPM
Brain Frontal Cortex BA9
87.1 TPM
Brain Nucleus accumbens basal ganglia
71.7 TPM
Brain Anterior cingulate cortex BA24
55.9 TPM
OUTRAS DOENÇAS (5)
melorheostosiscardiofaciocutaneous syndrome 3cardiofaciocutaneous syndromeRASopathy
HGNC:6840UniProt:Q02750
NRASGTPase NRasCandidate gene tested inAltamente restrito
FUNÇÃO

Ras proteins bind GDP/GTP and possess intrinsic GTPase activity

LOCALIZAÇÃO

Cell membraneGolgi apparatus membrane

VIAS BIOLÓGICAS (2)
Signaling by moderate kinase activity BRAF mutantsNeutrophil degranulation
MECANISMO DE DOENÇA

Leukemia, juvenile myelomonocytic

An aggressive pediatric myelodysplastic syndrome/myeloproliferative disorder characterized by malignant transformation in the hematopoietic stem cell compartment with proliferation of differentiated progeny. Patients have splenomegaly, enlarged lymph nodes, rashes, and hemorrhages.

EXPRESSÃO TECIDUAL(Ubíquo)
Linfócitos
77.3 TPM
Fibroblastos
52.5 TPM
Skin Not Sun Exposed Suprapubic
25.1 TPM
Esôfago - Mucosa
24.4 TPM
Skin Sun Exposed Lower leg
23.4 TPM
OUTRAS DOENÇAS (13)
neurocutaneous melanocytosislarge congenital melanocytic nevusthyroid cancer, nonmedullary, 2colorectal cancer
HGNC:7989UniProt:P01111

Variantes genéticas (ClinVar)

593 variantes patogênicas registradas no ClinVar.

🧬 NRAS: NM_002524.5(NRAS):c.149C>A (p.Thr50Asn) ()
🧬 NRAS: NM_002524.5(NRAS):c.328C>T (p.Pro110Ser) ()
🧬 NRAS: NM_002524.5(NRAS):c.*3102A>G ()
🧬 NRAS: NM_002524.5(NRAS):c.503T>C (p.Met168Thr) ()
🧬 NRAS: NM_002524.5(NRAS):c.286T>C (p.Tyr96His) ()
Ver todas no ClinVar

Vias biológicas (Reactome)

51 vias biológicas associadas aos genes desta condição.

Spry regulation of FGF signaling Frs2-mediated activation ARMS-mediated activation Signalling to p38 via RIT and RIN RAF activation MAP2K and MAPK activation Negative feedback regulation of MAPK pathway Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF1 fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants Signaling by RAF1 mutants SHOC2 M1731 mutant abolishes MRAS complex function Gain-of-function MRAS complexes activate RAF signaling MAPK3 (ERK1) activation Signal transduction by L1 Uptake and function of anthrax toxins MAP3K8 (TPL2)-dependent MAPK1/3 activation Signaling by MAP2K mutants SOS-mediated signalling Activation of RAS in B cells Constitutive Signaling by Ligand-Responsive EGFR Cancer Variants SHC1 events in ERBB2 signaling SHC1 events in ERBB4 signaling Signaling by SCF-KIT Signalling to RAS p38MAPK events GRB2 events in EGFR signaling SHC1 events in EGFR signaling Downstream signal transduction GRB2 events in ERBB2 signaling Tie2 Signaling EGFR Transactivation by Gastrin DAP12 signaling SHC-related events triggered by IGF1R FCERI mediated MAPK activation NCAM signaling for neurite out-growth Ras activation upon Ca2+ influx through NMDA receptor VEGFR2 mediated cell proliferation CD209 (DC-SIGN) signaling Constitutive Signaling by EGFRvIII SHC-mediated cascade:FGFR1 FRS-mediated FGFR1 signaling SHC-mediated cascade:FGFR2 FRS-mediated FGFR2 signaling SHC-mediated cascade:FGFR3 FRS-mediated FGFR3 signaling FRS-mediated FGFR4 signaling SHC-mediated cascade:FGFR4

Diagnóstico

Os sinais que médicos procuram e os exames que confirmam

Carregando...

Tratamento e manejo

Remédios, cuidados de apoio e o que precisa acompanhar

Pipeline de tratamentos
Pipeline regulatório — de medicamentos já aprovados a drogas em pesquisa exploratória.
2Fase 29
1Fase 110
·Pré-clínico1
Medicamentos catalogadosEnsaios clínicos· 0 medicamentos · 20 ensaios
Carregando informações de tratamento...

Onde tratar no SUS

Hospitais de referência no Brasil e o protocolo oficial do SUS (PCDT)

🇧🇷 Atendimento SUS — Tumor de células dendríticas

🗺️

Selecione um estado ou use sua localização para ver resultados.

Dados de DATASUS/CNES, SBGM, ABNeuro e Ministério da Saúde. Sempre confirme a disponibilidade diretamente com o estabelecimento.

Pesquisa ativa

Ensaios clínicos abertos e novidades científicas recentes

🟢 Recrutando agora

13 pesquisas recrutando participantes. Converse com seu médico sobre a possibilidade de participar.

Outros ensaios clínicos

56 ensaios clínicos encontrados, 20 ativos.

Distribuição por fase
Ver todos no ClinicalTrials.gov
🧪 Está conduzindo uma pesquisa?
Divulgue para pacientes e familiares que acompanham esta doença.
Divulgar pesquisa →

Publicações mais relevantes

Timeline de publicações
86 papers (10 anos)
#1

Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.

Haematologica2026 Jan 15

Not available.

#2

Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity.

International journal of molecular sciences2025 Jul 04

Cyclophosphamide (CPX) is an alkylating agent commonly used for various hematological and solid malignancies. In addition to its use as a cytotoxic agent to directly kill tumor cells, numerous immunomodulatory properties of CPX in the tumor microenvironment (TME) of several cancer types have also been documented. These properties include the selective depletion of immune-suppressive regulatory T cells (Tregs), triggering of immunogenic cell death (ICD) and enhanced antigen presentation, and release of type I interferons (IFNs). Moreover, preclinical models as well as human clinical trials have investigated the efficacy of the low-dose "metronomic" scheduling of CPX in combination with immunotherapies such as immune checkpoint inhibitors, dendritic cell tumor vaccines, and tumor antigen peptide vaccines. The metronomic dosing schedule involves administering a continuous (or frequent, such as daily) low dose of chemotherapy rather than using the canonical approach of administering the maximum tolerated dose. Despite the approval of immune checkpoint inhibitors for clinical usage against an increasing number of cancers, many malignancies simply do not respond to checkpoint inhibition, in part due to the heterogeneous intratumoral network of immune-suppressive cell populations. The immunomodulatory effects of cyclophosphamide have strong translational applicability and could serve to enhance and bolster anti-tumor immunity, potentially synergizing with immune checkpoint inhibitors and other existing immunotherapy agents.

#3

EBV-positive inflammatory follicular dendritic cell sarcoma of fibroblastic reticular cell phenotype arising in intrapancreatic accessory spleen.

Journal of clinical and experimental hematopathology : JCEH2025

Epstein-Barr Virus (EBV)-positive inflammatory follicular dendritic cell sarcoma (EBV-IFDCS) is a rare tumor of low malignant potential. Abundant lymphocytes and plasma cells often infiltrate into this tumor tissue with lymphoid follicles and sarcoid-like granulomas, so that the differential diagnosis of this tumor includes inflammatory lesions such as IgG4-related disease, morphologically. This tumor typically arises in the spleen or liver, and shows follicular dendritic cell (FDC)-like immunophenotype. Here we presented a case of EBV-IFDCS arising in intrapancreatic accessory spleen, which was preoperatively considered as a pancreatic tumor. Immunohistochemistry revealed its fibroblastic reticular cell-like phenotype, namely alpha SMA, l-caldesmon, tenascin C, and transglutaminase II positivity, while FDC marker expression such as CD21 and clusterin was focal. Positivity for EBV-encoded small RNA in situ hybridization (EBER ISH) distinguished it from inflammatory lesions or conventional FDC sarcoma. The differential diagnosis of EBV-IFDCS is broad, ranging from non-neoplastic lesions to sarcoma, particularly when it arises in unusual sites. Therefore, careful gross and microscopic examination and adequate immunohistochemistry application including EBER ISH are important to diagnose it properly.

#4

Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.

Oncology research2025

Malignant melanoma, characterized by its high metastatic potential and resistance to conventional therapies, presents a major challenge in oncology. This review explores the current status and advancements in tumor vaccines for melanoma, focusing on peptide, DNA/RNA, dendritic cell, tumor cell, and neoantigen-based vaccines. Despite promising results, significant challenges remain, including the immunosuppressive tumor microenvironment, patient heterogeneity, and the need for more effective antigen presentation. Recent strategies, such as combining vaccines with immune checkpoint inhibitors (ICIs), aim to counteract immune evasion and enhance T cell responses. Emerging approaches, including personalized neoantigen vaccines and the use of self-amplifying RNA platforms, hold promise for overcoming tumor heterogeneity and improving vaccine efficacy. Additionally, optimizing vaccine delivery systems through nanotechnology and genetic modifications is essential for increasing stability and scalability. This review highlights the potential of these innovative strategies to address current limitations, with a focus on how future research can refine and combine these approaches to improve melanoma treatment outcomes.

#5

Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.

Materials today. Bio2025 Aug

Nanodrug delivery systems (NDDSs) have demonstrated broad application prospects in disease treatment, prevention, and diagnosis due to their nanoscale size advantages and high drug-loading capacity. However, their clinical translation still faces multiple challenges, including rapid clearance by the reticuloendothelial system (RES), nonspecific targeting, and insufficient efficiency in crossing biological barriers. Cell membrane-coated biomimetic delivery systems (CMC-BDS), which integrates natural cell membranes onto nanoparticle (NPs) surfaces, provides nanodrugs with a versatile "biomimetic cloak," representing a highly promising surface engineering strategy. This approach enables nanocarriers to inherit the intrinsic biological properties of different cell sources, endowing them with immune evasion, prolonged circulation, dynamic targeting, biocompatibility, and biodegradability, while supporting the integration of diverse biomedical functions. Furthermore, surface functionalization modifications can enhance their programmability, multifunctionality, and biointerface adaptability, thereby optimizing targeted delivery efficiency and extending in vivo circulation time. This review first outlines the development and key preparation steps of cell membrane coating technology. It then discusses the selection strategies for various cell membrane types-including leukocyte, erythrocyte, platelet, dendritic cell, tumor cell, and bacterial membranes-while comparing their respective advantages and limitations. Finally, the review highlights recent advances in applying cell membrane-coated nanoparticles (CMC-NPs) for treating tumors, ischemic stroke, and inflammatory diseases.

Publicações recentes

Ver todas no PubMed

📚 EuropePMC173 artigos no totalmostrando 86

2026

Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.

Haematologica
2025

EBV-positive inflammatory follicular dendritic cell sarcoma of fibroblastic reticular cell phenotype arising in intrapancreatic accessory spleen.

Journal of clinical and experimental hematopathology : JCEH
2025

Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.

Oncology research
2025

Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity.

International journal of molecular sciences
2025

Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.

Materials today. Bio
2025

A Rare Case of Follicular Dendritic Cell Sarcoma of Tonsil-Clinical Report.

Indian journal of otolaryngology and head and neck surgery : official publication of the Association of Otolaryngologists of India
2025

[Cell therapy with tumor infiltrating lymphocytes; a therapeutic alternative for malignant melanoma and soon also other types of cancer].

Lakartidningen
2025

Radiotherapy for cytokeratin-positive interstitial reticulum cell (CIRC) tumor on epicardium: a case report.

International cancer conference journal
2024

Widespread Cutaneous Indeterminate Dendritic Cell Tumor (IDCT) With ETV3::NOAC2 Rearrangement Successfully Treated With PUVA Therapy: A Case Report.

Case reports in hematology
2024

An in vitro investigation into the cytotoxic impact of antigen-presenting dendritic cell-tumor infiltrating lymphocytes on ovarian cancer cells.

BMC cancer
2024

Blastic plasmacytoid dendritic cell neoplasm: Two case reports.

World journal of clinical oncology
2024

A rare case of an EBV-positive inflammatory follicular dendritic cell tumor of the spleen.

Journal of surgical case reports
2024

Immunotherapeutic allogeneic dendritic cell and autologous tumor cell fusion vaccine alone or combined with radiotherapy in canine oral malignant melanoma is safe and potentially effective.

Frontiers in veterinary science
2024

A sarcomatoid malignancy originating in the right cervical lymph nodes with atypical pathological characteristics: a case report of an incidental finding.

AME case reports
2024

Malignant Dendritic Cell Sarcomas in the Skin: 2 Cases of Rare Sarcoma Subtypes With Literature Review.

The American Journal of dermatopathology
2024

Overall clinical course of indeterminate dendritic cell tumor patients without skin lesions: A rare case report.

World journal of clinical cases
2024

A Rare Case of Follicular Dendritic Cell Tumor of the Abdominal Cavity Visualized by 18 F-AlF-NOTA-Octreotide PET/CT.

Clinical nuclear medicine
2024

[Plasmacytoid dendritic cell tumor of the testis in a child: report of a case].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2024

[Blastic plasmacytoid dendritic cell tumor treated with DVT regimen: a case report and literature review].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2024

Global trends in tumor microenvironment-related research on tumor vaccine: a review and bibliometric analysis.

Frontiers in immunology
2023

Recurrent Chemotherapy Treated Indeterminate Dendritic Cell Tumor: Case Report and Literature Review.

Clinical, cosmetic and investigational dermatology
2023

Inflammatory Pseudotumor of the Liver.

Surgical pathology clinics
2023

Primary cutaneous interdigitating dendritic cell sarcoma (IDCS): Report of a new case and literature review.

Pathology, research and practice
2023

Magnetic nanoparticles enhance the cellular immune response of dendritic cell tumor vaccines by realizing the cytoplasmic delivery of tumor antigens.

Bioengineering & translational medicine
2023

Blastic plasmacytoid dendritic cell tumor in children.

Minerva pediatrics
2022

[Clinical study of mesenchymal stem cells from third-party donors in the treatment of refractory late onset hemorrhagic cystitis after allogeneic hematopoietic stem cell transplanation].

Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi
2022

Blastic Indeterminate Dendritic Cell Tumor Associated With Chronic Myelomonocytic Leukemia.

The American Journal of dermatopathology
2022

Development of a Dendritic Cell/Tumor Cell Fusion Cell Membrane Nano-Vaccine for the Treatment of Ovarian Cancer.

Frontiers in immunology
2023

Typical leonine facies in a patient with indeterminate dendritic cell tumor.

International journal of dermatology
2021

Follicular dendritic cell sarcoma.

Pathologica
2021

Hepatic inflammatory pseudotumor-like follicular dendritic cell tumor with hepatic lymphoma history: A case report and literature review.

Medicine
2021

A new PD-1-specific nanobody enhances the antitumor activity of T-cells in synergy with dendritic cell vaccine.

Cancer letters
2021

Inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: a case report and approach to differential diagnosis.

Radiology case reports
2021

Follicular dendritic cell tumor in the context of a Castleman disease in a patient with Diffuse Large B Cell Lymphoma: Diagnosis and follow-up with 18F-FDG PET/CT.

Revista espanola de medicina nuclear e imagen molecular
2021

Hepatic inflammatory pseudotumor-like follicular dendritic cell tumor: a case report.

Journal of medical case reports
2021

Disseminated Indeterminate Dendritic Cell Tumor: A Rare Presentation.

Indian dermatology online journal
2021

A Pedigree Analysis and Clonal Correlations of the Coexistence of B-Cell Lymphoma and Histiocytic/Dendritic Cell Tumor.

International journal of surgical pathology
2021

Interdigitating Dendritic Cell Tumor of Submandibular Lymph Node: Case Report and Literature Review.

Iranian journal of pathology
2021

Dendritic Cell Tumor Vaccination via Fc Gamma Receptor Targeting: Lessons Learned from Pre-Clinical and Translational Studies.

Vaccines
2021

Indeterminate Dendritic Cell Tumor With Persistent Complete Metabolic Response to BRAF/MEK Inhibition.

HemaSphere
2020

Immune Checkpoint Blockade Enhances Immune Activity of Therapeutic Lung Cancer Vaccine.

Vaccines
2020

[Dendritic cell tumor vaccine assisted by Tiaohengfang polysaccharides enhances immune function of S180 tumor-bearing mice and inhibits tumor growth].

Xi bao yu fen zi mian yi xue za zhi = Chinese journal of cellular and molecular immunology
2020

[Clinicopathological characteristics of indeterminate dendritic cell tumor of four cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2020

Descriptive Analysis of Histiocytic and Dendritic Cell Neoplasms: A Single-Institution Experience.

Yonsei medical journal
2020

Indeterminate dendritic cell tumor in the pancreas.

Journal of surgical case reports
2020

Indeterminate Dendritic Cell Tumor as Cutaneous Involvement of Chronic Myelomonocytic Leukemia Successfully Treated With Phototherapy.

The American Journal of dermatopathology
2020

Dendritic Cell-Based Therapy Using LY6E Peptide with a Putative Role Against Colorectal Cancer.

ImmunoTargets and therapy
2020

Spinal Cord Compression Caused by Fibroblastic Reticular Cell Tumor (FRCT) Originating from Thoracic Spine.

World neurosurgery
2019

Relative hematopoietic stem cell transplantation for the treatment of blastic plasmacytoid dendritic cell neoplasm: a case report and literature review.

International journal of clinical and experimental pathology
2019

Pancreatic Inflammatory Pseudotumor-Like Follicular Dendritic Cell Tumor.

Case reports in pathology
2019

Imaging findings of inflammatory pseudotumor-like follicular dendritic cell tumors of the liver: Two case reports and literature review.

World journal of gastroenterology
2020

Post-scabietic nodules: Mimicker of infantile indeterminate cell histiocytosis and potential diagnostic pitfall.

Journal of cutaneous pathology
2019

Histiocytic and Dendritic Cell Neoplasms.

Surgical pathology clinics
2019

Paraneoplastic disorders associated with miscellaneous neoplasms with focus on selected soft tissue and Undifferentiated/ rhabdoid malignancies.

Seminars in diagnostic pathology
2019

Host Immunity Following Near-Infrared Photoimmunotherapy Is Enhanced with PD-1 Checkpoint Blockade to Eradicate Established Antigenic Tumors.

Cancer immunology research
2018

A Case of Indeterminate Dendritic Cell Tumor: A Rare Neoplasm with Langerhans Cell Lineage.

Annals of dermatology
2018

Predictors of Response to Autologous Dendritic Cell Therapy in Glioblastoma Multiforme.

Frontiers in immunology
2018

Interdigitating dendritic cell tumor: A rare case report with review of literature.

Journal of cancer research and therapeutics
2018

Indeterminate Dendritic Cell Tumor: A Report of Two New Cases Lacking the ETV3-NCOA2 Translocation and a Literature Review.

The American Journal of dermatopathology
2018

Vaccine therapy in hematologic malignancies.

Blood
2018

Recurrent Indeterminate Dendritic Cell Tumor of the Skin.

Journal of pathology and translational medicine
2018

Inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen.

The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology
2017

[Clinicopathologic and molecular characteristics of malignant gastrointestinal neuroectodermal tumors].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2018

Cellular Immunotherapy for Hematologic Malignancies: Beyond Bone Marrow Transplantation.

Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2017

Aggressive Indeterminate Dendritic Cell Tumor Mimicking Scalp Angiosarcoma.

Annals of dermatology
2017

Chronic myelomonocytic leukemia masquerading as cutaneous indeterminate dendritic cell tumor: Expanding the spectrum of skin lesions in chronic myelomonocytic leukemia.

Journal of cutaneous pathology
2017

Advances in immunotherapy in multiple myeloma.

Current opinion in oncology
2017

Indeterminate Dendritic Cell Tumor in Thoracic Spine: A Case Report.

World neurosurgery
2017

Splenic Epstein-Barr Virus-Associated Inflammatory Pseudotumor.

Archives of pathology & laboratory medicine
2017

Hepatic inflammatory pseudotumour-like follicular dendritic cell tumor: A case report.

Molecular and clinical oncology
2017

[Indeterminate dendritic cell tumor:report of two cases].

Zhonghua bing li xue za zhi = Chinese journal of pathology
2017

Immunomonitoring reveals interruption of anergy after vaccination in a case of type-2-papillary renal cell carcinoma.

Immunotherapy
2016

Paraneoplastic Pemphigus Associated with Follicular Dendritic Cell Tumor in the Mediastinum.

Case reports in dermatological medicine
2015

Gene Expression Profile of Dendritic Cell-Tumor Cell Hybrids Determined by Microarrays and Its Implications for Cancer Immunotherapy.

Journal of immunology research
2015

The impact of dendritic cell-tumor fusion cells on cancer vaccines - past progress and future strategies.

Immunotherapy
2015

Epstein-Barr virus-associated inflammatory pseudotumor presenting as a colonic mass.

Human pathology
2015

Primary Indeterminate Dendritic Cell Tumor of Skin Correlated to Mosquito Bite.

Medicine
2016

A case of indeterminate dendritic cell tumor presenting with leonine facies.

Journal of cutaneous pathology
2016

Indeterminate Dendritic Cell Tumor: A Case Report of a Rare Langerhans Cell Lineage Disease.

Journal of pathology and translational medicine
2015

Resection is an effective treatment for recurrent follicular dendritic cell sarcoma from retroperitoneum: unusual presentation of a rare tumor.

International journal of clinical and experimental medicine
2015

Follicular dendritic cell sarcoma with extensive lymph node involvement: A case report.

Oncology letters
2014

Follicular Dendritic Cell Sarcoma Mediastinum - a case report.

Indian journal of surgical oncology
2015

Clinicopathological features of angiomatoid fibrous histiocytoma: a series of 21 cases with variant morphology.

International journal of clinical and experimental pathology
2015

Inflammatory Pseudotumor-like Follicular Dendritic Cell Tumor of the Spleen: Case Report and Review of the Literature.

Magnetic resonance in medical sciences : MRMS : an official journal of Japan Society of Magnetic Resonance in Medicine
2015

Multimodality imaging of Epstein-Barr virus-associated inflammatory pseudotumor-like follicular dendritic cell tumor of the spleen: case report and literature review.

Clinical imaging
2015

Interdigitating dendritic cell sarcoma.

Journal of the National Comprehensive Cancer Network : JNCCN
Ver todos os 173 no EuropePMC

Associações

Organizações que acompanham esta doença — pra ter apoio e orientação

Ainda não temos associações cadastradas para Tumor de células dendríticas.

É de uma associação que acompanha esta doença? Fale com a gente →

Comunidades

Grupos ativos de quem convive com esta doença aqui no Raras

Ainda não existe comunidade no Raras para Tumor de células dendríticas

Pacientes, familiares e cuidadores se organizam em comunidades pra compartilhar experiências, fazer perguntas e se apoiar. Você pode ser o primeiro.

Tire suas dúvidas

Perguntas, dicas e experiências compartilhadas aqui na página

Participe da discussão

Faça login para postar dúvidas, compartilhar experiências e interagir com especialistas.

Fazer login

Doenças relacionadas

Doenças com sintomas parecidos — ajudam quem ainda está buscando diagnóstico

Referências e fontes

Bases de dados externas citadas neste artigo

Publicações científicas

Artigos indexados no PubMed ligados a esta doença no grafo RarasNet — título, periódico e PMID direto da fonte, sem intermediação de IA.

  1. Common ancestral origin of indeterminate dendritic cell tumor and chronic myelomonocytic leukemia in clonal hematopoiesis.
    Haematologica· 2026· PMID 41537315mais citado
  2. Effects of the Alkylating Agent Cyclophosphamide in Potentiating Anti-Tumor Immunity.
    International journal of molecular sciences· 2025· PMID 40650216mais citado
  3. EBV-positive inflammatory follicular dendritic cell sarcoma of fibroblastic reticular cell phenotype arising in intrapancreatic accessory spleen.
    Journal of clinical and experimental hematopathology : JCEH· 2025· PMID 41016808mais citado
  4. Tumor Vaccines for Malignant Melanoma: Progress, Challenges, and Future Directions.
    Oncology research· 2025· PMID 40746887mais citado
  5. Stealth missiles with precision guidance: A novel multifunctional nano-drug delivery system based on biomimetic cell membrane coating technology.
    Materials today. Bio· 2025· PMID 40528836mais citado

Bases de dados e fontes oficiais

Identificadores e referências canônicas usadas para montar este verbete.

  1. ORPHA:98289(Orphanet)
  2. MONDO:0020082(MONDO)
  3. GARD:8317(GARD (NIH))
  4. Variantes catalogadas(ClinVar)
  5. Busca completa no PubMed(PubMed)
  6. Q56014397(Wikidata)

Dados compilados pelo RarasNet a partir de fontes abertas (Orphanet, OMIM, MONDO, PubMed/EuropePMC, ClinicalTrials.gov, DATASUS, PCDT/MS). Este conteúdo é informativo e não substitui avaliação médica.

Conteúdo mantido por Agente Raras · Médicos e pesquisadores podem colaborar

Tumor de células dendríticas
Compêndio · Raras BR

Tumor de células dendríticas

ORPHA:98289 · MONDO:0020082
CID-10
C96.4 · Outras neoplasias malignas e as não especificadas dos tecidos linfático, hematopoético e tecidos correlatos
Ensaios
20 ativos
MedGen
UMLS
C1301364
EuropePMC
Wikidata
Papers 10a
DiscussaoAtiva

Nenhuma novidade ainda. O agente esta monitorando.

0membros
0novidades